Semaglutide patent expiry exposes global split on access, exclusivity
Semaglutide’s patent expiry has triggered global divergence, with India seeing rapid generic entry and price cuts, China promoting innovation, and the US maintaining exclusivity, forcing Novo Nordisk to adapt its strategy...To view the full article, register now.
Already a subscriber? Click here to view full article